# Biotech Growth Trust portfolio company AtaiBeckley to be acquired by Eli Lilly

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-portfolio-company-ataibeckley-to-be-acquired-by-eli-lilly/4121256598
- Published: 2026-07-17T07:40:42+01:00
- Author: Amilia Stone

Biotech Growth Trust plc (LON:BIOG) has noted the announcement on Thursday, 16 July
2026 that Eli Lilly and Company has announced its intention to acquire BIOG portfolio
company, AtaiBeckley Inc. for approximately $2.8 billion, or $6.75 a share, in cash
representing a 26% premium to AtaiBeckley’s closing price on Wednesday, 15 July 
2026.  

The offer also includes an additional approximately $1 billion in contingent value
right payments which are based on AtaiBeckley achieving certain development and 
regulatory milestones; if met, the aggregate purchase price would total $3.8 billion,
or $9.25 per share, representing a 73% premium.

AtaiBeckley is a clinical-stage biotechnology company focused on the development
of drugs for the treatment of psychiatric disorders.   BPL-003 (mebufotenin benzoate
nasal spray), AtaiBeckley’s lead program, was granted Breakthrough Therapy Designation
from the U.S. Food and Drug Administration and has initiated Phase 3 activities 
for treatment-resistant depression.

The Company’s holdings in AtaiBeckley represented 1.1% of the Company’s net asset
value (“NAV”) at the time of the announcement.   The transaction will be reflected
in the Company’s NAV as at close of business on 16 July, 2026, which will be announced
on Friday. 17 July 2026.

This acquisition is the latest in a series of successful M&A outcomes across the
portfolio this year – following Avidity Biosciences, Cidara Therapeutics, Amicus
Therapeutics, Apellis Pharmaceuticals, KalVista Pharmaceuticals, Esperion Therapeutics
and Nuvalent, Inc – which have contributed meaningfully to the Company’s performance.
It reinforces the conviction that investing in innovative small and mid-cap biotechnology
companies, where much of the sector’s breakthrough science is taking place, can 
create substantial value for shareholders over the long term.

> **Geoff Hsu of OrbiMed Capital LLC, Portfolio Manager of The Biotech Growth Trust
> PLC, commented:**
> _“AtaiBeckley is developing innovative treatments for psychiatric disorders, an
> area of significant unmet medical need. Its lead programme, BPL-003, has shown
> encouraging progress and results and has the potential to offer a differentiated
> treatment option for patients with treatment-resistant depression._
> _“Eli Lilly’s acquisition represents another successful outcome for BIOG and further
> validates our investment strategy. We continue to focus on identifying innovative
> biotechnology companies capable of delivering important new medicines and creating
> substantial value for shareholders, whether through clinical success, commercial
> execution or strategic transactions such as this.”_

Share on:
